Big update
30 Jul 2026
Files second quarter 2026 financial results
Shows how much money the company made or lost in the first half of 2026.
SEC 10-Q · filed 2026-07-30
View filing ↗
What's happening at Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026
Earnings
30 Jul 2026
Announces Q2 2026 earnings to shareholders
Company tells investors how it performed financially for the three months ending June 30, 2026.
SEC 8-K · filed 2026-07-30
View filing ↗
Corporate
13 Jul 2026
Presents corporate overview to investors
Company shares a presentation explaining its business strategy and current progress.
SEC 8-K · filed 2026-07-13
View filing ↗
Governance
26 Jun 2026
Stockholders elect three directors through June 2029
Shareholders voted to choose leaders who will guide the company for the next three years.
SEC 8-K · filed 2026-06-26
View filing ↗
Earnings
5 May 2026
Files first quarter 2026 financial results
Shows how much money the company made or lost in the first three months of 2026.
SEC 10-Q · filed 2026-05-05
View filing ↗
Earnings
5 May 2026
Announces Q1 2026 earnings to shareholders
Company tells investors how it performed financially for the three months ending March 31, 2026.
SEC 8-K · filed 2026-05-05
View filing ↗
Corporate
30 Apr 2026
PIPE-791 Phase 1b chronic pain trial meets safety goals
Company's drug candidate proved safe in 43 patients with arthritis and back pain in early testing.
SEC 8-K · filed 2026-04-30
View filing ↗
Common questions
How does Stocky track Contineum Therapeutics, Inc.'s company events?
Stocky reads Contineum Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
What was Contineum Therapeutics, Inc.'s most recent SEC filing?
Contineum Therapeutics, Inc.'s most recent tracked filing was a 10-Q on 30 Jul 2026: Files second quarter 2026 financial results.
Is this financial advice?
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.